%0 Journal Article
%T Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects
%A Baorui Liu
%A Fangjun Chen
%A Kai Xin
%A Lixia Yu
%A Qin Liu
%A Qin Wang
%A Xiao Wei
%J Archive of "Translational Oncology".
%D 2019
%R 10.1016/j.tranon.2019.02.008
%X Cancer vaccines, including peptide-based vaccines, have been considered a key tool of effective and protective cancer immunotherapy because of their capacity to provide long-term clinical benefit for tumors. Among a large number of explorations of peptide antigen-based vaccines, cancer-testis antigens (CTAs), which are activated in cancers but silenced in normal tissues (except testis tissue), are considered as ideal targets. Currently, personalized treatment for cancer has become a trend due to its superior clinical efficacy. Thus, we envisage rational selection of CTA peptides to design ˇ°personalizedˇ± CTA peptide vaccines. This review summarizes the advances in CTA peptide vaccine research and discusses the feasibility of establishing ˇ°personalizedˇ± CTA peptide vaccines
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423365/